LOS ANGELES, April 16 (Reuters) - Gilead Sciences Inc’s (GILD.O) experimental drug, GS-9450, was shown in a mid-stage trial to improve markers of liver damage in patients with non-alcoholic steatohepatitis, the most serious form of liver disease in people who drink little or no alcohol.
